Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00252213 · ClinicalTrials.gov registry record · Phase 1
BELIEVE Study: Nesiritide and Post Myocardial Infarction Left Ventricular Modeling
A Phase 1 study, sponsored by Mayo Clinic.
- Terminated
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT00252213: Clinical Trial Phase 1 study, sponsored by Mayo Clinic.
NCT00252213 is a Phase 1 study that was terminated before completion, run by Mayo Clinic. The registered enrollment target is 24 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00252213, a Phase 1 study, was terminated before completion, sponsored by Mayo Clinic.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
This study is being done to determine the effects (good and bad) of intravenous infusion of a human brain natriuretic peptide (BNP), Natrecor (nesiritide), a hormone produced by the heart in persons who have just suffered a heart attack. The human BNP, Natrecor (nesiritide) has been approved by the United States Food and Drug Administration (FDA) to be given intravenously for the management of acute heart failure. It is unknown if human BNP may have good effects on the pumping function of the heart after a heart attack.
Interventions
- DRUG Human BNP
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2002-08 |
| Est. Completion | 2006-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00252213
The ClinicalTrials.gov registry entry for NCT00252213 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Human BNP is the first listed.
NCT00252213 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00252213 about?
NCT00252213 is a clinical study titled "BELIEVE Study: Nesiritide and Post Myocardial Infarction Left Ventricular Modeling". This study is being done to determine the effects (good and bad) of intravenous infusion of a human brain natriuretic peptide (BNP), Natrecor (nesiritide), a hormone produced by the heart in persons who have just suffered a heart attack. The human BNP, Natrecor (nesiritide) has been approved by the ...
What is the current status of trial NCT00252213?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2002-08. Estimated completion is 2006-01.
What interventions are being tested in trial NCT00252213?
The interventions under investigation include: Human BNP (DRUG).
Who is sponsoring clinical trial NCT00252213?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.